An automated data integration platform for interpreting genomic data and reporting treatment options in molecular tumor boards

someone writes something on a flipchart

Aims of this collaborative project

With growing knowledge of biomarkers and resent developments in sequencing techniques, nowaday genomic data is considered as extremely valuable and indispensable for the diagnosis and therapy recommendation particularly of tumor patients. The complexity of interpreting genomic data is hindering its application in the routine clinical context.
In the MTB-Report project the consortium aims to develop a tool to support the decision finding in a molecular tumor board (MTB). Biomarkers and other omics data from the patient will be compared to a multitude of available data bases in order to find case studies with a  parameter set equivalent to the patient’s one. Based on tumor type and certainty of the study an evidence level is assigned and used to propose the most relevant to the MTB in form a short report.

For access to the clinical data and to ensure data privacy the tool will be embedded in the IT-infrastructure. Clinical experts will define use cases for an optimal usage of the reporting tool and will validate the results.

Project partners

Department of Medical Bioinformatics (UMG)

Prof. Tim Beißbart
Dr. Jürgen Dönitz

Department of Medical Informatics

Prof Ulrich Sax

Department of Hematology and Medical Oncology

Prof. Annalen Bleckmann (now Münster University Hospital, UKM)
Dr. Raphael Koch

Current theses offers

Bachelor thesis (including practical course): Creating a drug ontology by automatic information retrieval from DrugBank and other sources for application in molecular tumor boards

At the department of Medical Bioinformatics in cooperation with the department of Medical Informatics and the department of Haematology and Oncology we offer a Bachelor thesis in the context of the MTB-Report Project.

In the MTB Report we aim at developing tools to support the information process to recommend treatment options based on the patient’s biomarkers. One important part here is the standardization and annotation of drugs. Drugs can be mentioned with a drug name, drug class or trade name. For an automatic processing a classification is needed. With additional information like the annotation of the target of the drug, the affected target of the drug and the involved genes up- and down streams open the options for further analysis. There is already a lot of information, however, a comprehensive information resource that will cover the needs of the MTB project.

Main tasks will be:

  • Identifying valuable and usable external resources
  • Automatic extraction and preparation of information of external resources and from the project tools
  • Design of an ontology which covers the information required by the project in a semantic way
  • Populate the ontology and link to external resources
  • Validate the new resource in the scope of the project

Focus: Applied Computer Science, Medical Informatics

Supervisor: Dr. Jürgen Dönitz

                         Current Theses Offers by the Institute of Medical Informatics

In the context of the MTB project, two Bachleor-/Master- theses are currently offered by the Institute of Medical Informatics: 

1. Topic: Support of the molecular tumor board with cBioPortal.

2. Topic: Comparison of current patient similarity searches using two example data sets

For more information, please see here: or contact Jonas Hügel: 

MTB-Report Seminar

The MTB-Report Seminar Series is a joint event of all partners and members of the MTB-Report project. Monthly, members of the different groups as well as invited speakers present their projects.

Unless announced otherwise, the seminar takes place monthly on the fourth Wednesday at 10.30am . Due to the SARS-CoV-2 related measures, the seminar takes place via video conference .

Coordination/Contact: Dr. Jürgen Dönitz 

Date: 24th of February 10.30 am

Speaker: Nicole Schmidt

Title: "Wetlab workflow - Drug screening"

Abstract: An evidence-driven reporting system developed for molecular tumor boards was utilized to detect relevant genetic alterations in primary T-cell lymphoma (TCL) samples and cell line models and identified potential therapeutics. In order to pre-clinically validate potential therapeutic targets and to assess novel therapeutic strategies in vitro we performed a cell viability drug screening using established TCL cell lines. This presentation will summarize the wetlab workflow and drug screen approach.


Former and upcoming Talks

Publications from preliminary work

Perera-Bel J., Leha A., Beißbarth T.
Bioinformatic Methods and  Resources for Biomarker Discovery, Validation, Development, and  Integration.
In: Badve S., Kumar G. (eds) Predictive Biomarkers in  Oncology. Springer, Cham. (2019)

Perera-Bel J, Hutter B, Heining C, Bleckmann A, Fröhlich M, Fröhling S, Glimm H, Brors B, Beißbarth T.
From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Genome  Med. 2018 Mar 15;10(1):18. doi:10.1186/s13073-018-0529-2. PubMed PMID: 29544535;

Contact data of the coordinator


Prof. Dr. Tim Beißbarth

contact information

That might also interest you

Follow us